Table 2. All hematologic and non-hematologic adverse events: worst grade per patient in all cycles in at least 25% of all patients and / or ≥ grade 3 (n = 19).
| Adverse Event | Any Grade | Grade 3 | Grade 4 | |||
|---|---|---|---|---|---|---|
|
| ||||||
| No. of Patients | % | No. of Patients | % | No. of Patients | % | |
|
| ||||||
| Total | 19 | 100 | 10 | 53 | 1 | 5 |
| Fatigue | 14 | 74 | 4 | 21 | 0 | 0 |
| Hyperlipidemia | 14 | 74 | 0 | 0 | 0 | 0 |
| WeightLoss | 14 | 74 | 0 | 0 | 0 | 0 |
| Dysguesia | 13 | 68 | 0 | 0 | 0 | 0 |
| Hyperglycemia | 12 | 63 | 1 | 5 | 1 | 5 |
| Mucositis | 12 | 63 | 2 | 11 | 0 | 0 |
| Diarrhea | 11 | 58 | 0 | 0 | 0 | 0 |
| Epistaxis | 10 | 53 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 10 | 53 | 0 | 0 | 0 | 0 |
| Anorexia | 9 | 47 | 1 | 5 | 0 | 0 |
| Rash | 8 | 42 | 0 | 0 | 0 | 0 |
| Pain | 6 | 32 | 0 | 0 | 0 | 0 |
| Nail ridging | 6 | 32 | 0 | 0 | 0 | 0 |
| Neutropenia | 5 | 26 | 1 | 5 | 0 | 0 |
| Elevated AST, ALT or AlkPhos | 5 | 26 | 2 | 11 | 0 | 0 |
| Infection | 3 | 16 | 1 | 5 | 0 | 0 |
| Electrolyte abnormalities | 3 | 16 | 2 | 11 | 0 | 0 |
| Anemia | 2 | 11 | 1 | 5 | 0 | 0 |
| Injury | 1 | 5 | 1 | 5 | 0 | 0 |
| Retinal Detachment | 1 | 5 | 1 | 5 | 0 | 0 |
| Thromboembolism | 1 | 5 | 1 | 5 | 0 | 0 |
| Dehydration | 1 | 5 | 1 | 5 | 0 | 0 |
a
Graded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Abbreviations: ALT, alanine amino-transferase; AST, aspartate amino-transferase